Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma
Authors:
- Sridevi RajeeveSRSridevi Rajeeve
- Matt WilkesMWMatt Wilkes
- Nicole ZahradkaNZNicole Zahradka
- Lewis TomalinLTLewis Tomalin
- Mujahid QuidwaiMQMujahid Quidwai
- Darren PanDPDarren Pan
- Nicholas J. CalafatNCNicholas J. Calafat
- Martin CusackMCMartin Cusack
- Adolfo AlemanAAAdolfo Aleman
- Kseniya SerebryakovaKSKseniya Serebryakova
- Katerina KappesKKKaterina Kappes
- Hayley JacksonHJHayley Jackson
Open Access
- 5 May 2026
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (12)
Abstract
BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized treatment for relapsed/refractory multiple myeloma (RRMM). However, cytokine release syndrome (CRS), a common and potentially severe complication, requires inpatient monitoring, limiting access and increasing costs. Wearable devices could support outpatient CAR-T delivery, but feasibility for CRS detection versus standard care remains unproven. METHODS: We conducted a prospective, single-center observational pilot study to assess the feasibility of using wearable devices for monitoring vital signs and detecting CRS. Thirty patients receiving idecabtagene vicleucel (ide-cel) or ciltacabtagene autoleucel (cilta-cel) were enrolled; 25 with sufficient monitoring data were evaluable. Sensors collected skin and axillary temperature, oxygen saturation, respiratory and heart rate, and motion. Peripheral blood cytokines were analyzed pre- and postinfusion using a multiplex proteomic platform. The primary outcome was feasibility, assessed by CRS detection sensitivity and specificity; secondary outcomes included adherence, lead time, and performance of models integrating wearable and cytokine data. RESULTS: CRS occurred in 20 of 25 patients. The best-performing wearable model detected 18 or 20 CRS episodes with a sensitivity of 0.72 (mean 0.75; 95% CI 0.60–0.91) and a specificity of 0.80 (mean 0.76; 95% CI 0.68–0.84), and a median lead time of 7:00 hours before nursing recognition. Median adherence during high-risk periods was 71%. Cytokine changes paralleled temperature elevations, and IFN-γ emerged as a consistent biomarker. CONCLUSION: Wearable devices are feasible for early CRS detection and may support outpatient CAR-T care. Larger outpatient studies are warranted. TRIAL REGISTRATION: This study did not meet the criteria for ClinicalTrials.gov registration.Keywords
Funding Information
- NA (NA)
- NIH (R01 CA244899)
- NIH (R01 CA252222)
This publication has 32 references indexed in Scilit:
- Meta-analysis informed machine learning: Supporting cytokine storm detection during CAR-T cell TherapyJournal of Biomedical Informatics, 2023
- Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple MyelomaOncology and Therapy, 2023
- Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin LymphomaTransplantation and Cellular Therapy, 2023
- Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administrationeJHaem, 2021
- Myeloma CAR-T CRS Management With IL-1R Antagonist AnakinraClinical Lymphoma Myeloma and Leukemia, 2020
- Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL)Transplantation and Cellular Therapy, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell TherapyTransplantation and Cellular Therapy, 2019
- Using sweat to measure cytokines in older adults compared to younger adults: A pilot studyJournal of Immunological Methods, 2018
- Wearable Devices in Clinical Trials: Hype and HypothesisClinical Pharmacology & Therapeutics, 2017